Forty women were assessed for eligibility at gynaecology clinics in the region , of whom thirty premenopausal women scheduled for hysterectomy due to symptomatic fibroids were randomized to three groups , receiving ( @ ) GnRH agonist ( Goserelin ) , ( @ ) GnRH agonist + GnRH antagonist ( Goserelin and Cetrorelix ) or ( @ ) no treatment .